Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/24/2026 | Q4 | $109.8M | -- | -- | $0.08 | -- |
| 10/28/2025 | Q3 | $87M | $99.2M | $0.06 | -$0.09 | $0.15 |
| 08/06/2025 | Q2 | $73.7M | $81.5M | -$0.13 | -$0.16 | $0.03 |
| 05/06/2025 | Q1 | $62.5M | $65.8M | -$0.20 | -$0.21 | $0.01 |
| 02/25/2025 | Q4 | $60.5M | $71.4M | -$0.09 | -$0.26 | $0.18 |
| 11/06/2024 | Q3 | $37.3M | $44.8M | -$0.33 | -$0.43 | $0.10 |
| 08/14/2024 | Q2 | $29.1M | $30.9M | -$0.42 | -$0.53 | $0.11 |
| 05/14/2024 | Q1 | $15.1M | $49.6M | -$0.32 | -$0.73 | $0.41 |
| 02/27/2024 | Q4 | $11.4M | $13.5M | -$0.72 | -$0.80 | $0.08 |
| 11/03/2023 | Q3 | -- | -- | -$0.73 | -$0.91 | $0.18 |
| 08/08/2023 | Q2 | -- | -- | -$1.16 | -$1.25 | $0.09 |
| 05/09/2023 | Q1 | -- | -- | -$1.31 | -$1.26 | -$0.05 |
| 02/28/2023 | Q4 | -- | -- | -$1.18 | -$1.44 | $0.26 |
| 11/08/2022 | Q3 | -- | -- | -$1.89 | -$1.75 | -$0.14 |
| 08/04/2022 | Q2 | -- | -- | -$1.31 | -$1.42 | $0.11 |
| 05/05/2022 | Q1 | -- | -- | -$1.27 | -- | -- |
| 02/22/2022 | Q4 | -- | -- | -$1.42 | -- | -- |
| 11/04/2021 | Q3 | -- | -- | -$1.14 | -- | -- |
| 08/05/2021 | Q2 | -- | -- | -$0.84 | -- | -- |
| 05/06/2021 | Q1 | -- | -- | -$0.76 | -- | -- |
| 02/16/2021 | Q4 | -- | -- | -$0.79 | -- | -- |
| 11/05/2020 | Q3 | -- | -- | -$1.01 | -- | -- |
| 08/11/2020 | Q2 | -- | -- | -$0.94 | -- | -- |
| 05/12/2020 | Q1 | -- | -- | -$1.15 | -- | -- |
| 12/31/2019 | Q4 | -- | -- | -$0.36 | -- | -- |
| 09/30/2019 | Q3 | -- | -- | -$0.80 | -- | -- |
| 06/30/2019 | Q2 | -- | -- | -$0.46 | -- | -- |
| 03/31/2019 | Q1 | -- | -- | -$0.37 | -- | -- |
| 12/31/2018 | Q4 | -- | -- | -$0.31 | -- | -- |
Arcutis Biotherapeutics, Inc. reported $99.2M worth of top line sales in its most recent quarter.
Arcutis Biotherapeutics, Inc. announced earnings per share of $0.06 which represents a beat of analyst forecast a -$0.09 per share.
Arcutis Biotherapeutics, Inc. reported $90.5M that represents $0.68 per share over the last quarter.
Arcutis Biotherapeutics, Inc.'s earnings are forecast to decrease from -$1.16 per share to -$1.34 per share next year representing a decrease of -87.04%.
Arcutis Biotherapeutics, Inc.'s next earnings date is February 24, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.